SKB strikes Avandia deal after approval
Saturday 24 April 1999
On Wednesday SKB was given the green light to sell the drug by the US Food and Drug Administration's advisory panel, giving it access to the multi-billion dollar market for diabetes treatments.
The FDA ruled the drug was free of any links to unusual liver damage, giving SKB a crucial marketing edge over some type 2 diabetes treatments.
Yesterday a fierce battle for market share was in prospect when the FDA said Actos, a rival to Avandia produced by Eli Lilly and Takeda Chemical, was also not linked to liver damage.
Type 2 diabetes, a condition caused by the inability of the body to respond to natural insulin, affects around 100 million people across the world and 16 million in the US, most of them in the older age brackets.
Type 2 diabetes is the leading cause of adult blindness and kidney failure in the US. The conditions and its complications cause around 500 deaths a day in the US alone.
The new drugs help to reduce insulin resistance and allow the body to control its own blood-sugar level. SKB has completed more than 20 clinical trials involving 500-plus patients.
Rezulin, the rival drug developed by Warner Lambert, is expected to realise sales of $750m (pounds 465m) in spite of being linked to serious liver damage. The FDA allows the drug to be prescribed, but only alongside other treatments. Avandia can be used on its own.
Analysts expect Avandia and Actos to realise sales of $3bn between them within four years. Until now there were fears that these might also cause liver problems.
SKB's collaboration with Bristol-Myers Squibb will give Avandia an extra marketing push. Bristol-Myers is currently the market leader in diabetes treatments through its Glucophage product.
Howard Pien, president of SmithKline Beecham Pharmaceuticals, said: "Given the extensive experience of Bristol-Myers Squibb in bringing Glucophage to patients with type 2 diabetes, [we] understand well the urgent need to provide physicians with additional new therapeutic options."
- 1 Barbarians vs Samoa interrupted by sprinklers as fans criticise lack of Wi-Fi and poor seating at West Ham's Olympic Stadium
- 2 Caitlyn Jenner car crash: Driver who died in collision sued by surviving passengers for $18.5m
- 3 Watch the Supermoon live: How to see the brightest Moon of the year tonight
- 4 Hulk Hogan wants to be Donald Trump's running mate in the US Presidential election
- 5 Blood Moon and Supermoon: September to bring brightest – and dimmest – full Moon of the year on same night
Caitlyn Jenner car crash: Driver who died in collision sued by surviving passengers for $18.5m
Celebrity Big Brother 2015: Tila Tequila kicked off show after 'describing Hitler as a good man'
Watch the Supermoon live: How to see the brightest Moon of the year tonight
Hulk Hogan wants to be Donald Trump's running mate in the US Presidential election
Blood Moon and Supermoon: September to bring brightest – and dimmest – full Moon of the year on same night
Climate change: 2015 will be the hottest year on record 'by a mile', experts say
'Women only' train carriages: Jeremy Corbyn unveils radical move to tackle public harassment
Black holes are a passage to another universe, says Stephen Hawking
Iain Duncan Smith 'should resign over disability benefit death figures', says Jeremy Corbyn
Tony Blair attacks Jeremy Corbyn's 'Alice In Wonderland' politics
Stock up on canned food for stock market crash, warns former Gordon Brown adviser
iJobs Money & Business
£25000 - £30000 per annum: Recruitment Genius: From modest beginnings the comp...
£35000 - £40000 per annum: Recruitment Genius: From modest beginnings the comp...
£15000 - £65000 per annum: Recruitment Genius: This is an exciting opportunity...
£18000 - £20000 per annum: Recruitment Genius: This is a fantastic opportunity...